occult
hepat
b
viru
infect
among
antihbc
posit
blood
donor
necessit
substitut
screen
hbv
nat
safe
blood
transfus
still
remain
major
concern
far
effort
direct
fail
achiev
zero
residu
risk
transfus
transmit
hepat
b
viru
hbv
infect
direct
recent
publish
work
silva
et
al
journal
infect
reveal
remark
observ
report
show
hbv
dna
posit
blood
donor
sampl
antihbc
posit
enlighten
find
hbv
dna
posit
among
high
level
antihb
posit
donor
tertiari
care
centr
saudi
arabia
blood
unit
collect
isol
antihbc
posit
hbsag
posit
blood
unit
antihbc
antihb
posit
per
polici
health
ministri
antihbc
antihb
posit
blood
unit
util
isol
antihbc
blood
unit
reject
blood
unit
antihbc
antihb
posit
appear
transmit
hbv
infect
invers
correl
antihb
level
infect
blood
unit
low
level
iuml
antihb
infecti
observ
silva
et
al
hbv
dna
posit
among
antihbc
high
level
antihb
posit
blood
donor
pointer
toward
transfus
transmit
risk
involv
transfus
antihbc
antihb
posit
blood
unit
though
viral
load
sampl
low
copiesml
highli
infecti
transfus
immunocompris
patient
consid
volum
infecti
blood
transfus
amount
hbv
dna
infecti
minimum
infect
dose
hbv
chimpanze
viru
particl
mani
develop
countri
develop
countri
blood
unit
collect
still
screen
hbsag
antihbc
antihb
enzym
immuno
assay
mani
occas
result
indetermin
repeat
lead
higher
per
unit
cost
blood
screen
lot
reject
invalu
unit
collect
blood
exclus
gener
donor
isol
antihbc
posit
still
safeti
transfus
transmit
hbv
compromis
high
rate
reject
collect
blood
unit
exclus
antihbc
posit
blood
donor
lead
unceas
blood
shortag
blood
bank
hbv
screen
polici
collect
unit
blood
need
reassess
light
present
report
hbv
dna
test
prefer
instead
three
enzym
immuno
assay
test
hbv
dna
test
nat
collect
unit
blood
adopt
blood
bank
order
possibl
achiev
zero
risk
transfus
transmit
hbv
infect
also
reduc
reject
rate
preciou
unit
collect
blood
test
anti
hbc
outbreak
sever
acut
respiratori
syndrom
sar
result
number
infect
death
among
healthcar
worker
hcw
contact
sarsinfect
person
viru
classifi
provision
coronaviru
group
highli
contagi
treatment
infect
person
far
disappoint
first
evid
success
treatment
monkey
cynomolgu
macaqu
report
recent
use
alphainterferon
ifnalpha
administ
day
experiment
exposur
gave
success
wherea
drug
given
day
experiment
infect
significantli
reduc
viral
replic
excret
throat
lung
damag
also
reduc
compar
nontreat
monkey
review
articl
avian
infecti
bronchiti
ib
vaccin
strain
h
variou
characterist
vaccin
outlin
shall
mention
valuabl
properti
ib
vaccin
far
known
underlin
hypothesi
may
benefici
peopl
risk
sar
coronaviru
observ
ib
vaccin
h
abl
protect
broad
spectrum
differ
heterolog
serotyp
ib
challeng
virus
serotyp
differ
surfac
protein
respons
induct
neutral
antibodi
differ
chang
serotyp
ib
viru
therefor
conclud
protect
provid
vaccin
strain
h
depend
product
neutral
antibodi
also
due
induct
immunolog
reaction
role
nucleocapsid
protein
n
still
well
understood
may
play
import
role
protect
induc
specif
cytotox
lymphocyt
thu
vaccin
strain
h
may
respons
induct
protect
nucleocapsid
protein
order
evalu
import
cellular
mediat
immun
cmi
protect
ibv
infect
studi
would
necessari
explain
mechan
crossprotect
vaccin
strain
h
instanc
induct
interleukin
il
observ
interferon
poorli
induc
ibv
may
induc
vaccin
strain
passag
level
could
indic
play
limit
role
heterolog
protect
studi
marra
et
al
conclud
sar
coronaviru
novel
coronaviru
stavrinid
guttman
conclud
recent
sar
coronaviru
mammalianlik
replicas
protein
avianlik
n
protein
also
observ
mammalianavian
mosaic
protein
observ
extrem
import
consider
avian
coronaviru
possibl
candid
vaccin
sar
coronaviru
adequ
equip
laboratori
facil
propos
use
passag
h
strain
vaccin
preliminari
experiment
studi
monkey
passag
level
chosen
retent
crossprotect
characterist
vaccin
strain
h
passag
induc
low
level
interferon
lost
heterolog
protect
characterist
due
attenu
viru
b
order
produc
valuabl
immunolog
reaction
monkey
ib
vaccin
necessari
inocul
high
dose
live
viru
vaccin
exampl
median
embryo
infecti
dose
eid
intranas
intramuscularli
andor
subcutan
expect
viru
infecti
macaqu
therefor
high
dose
requir
order
achiev
adequ
respons
immun
system
year
avian
ib
infect
occur
worldwid
report
infect
among
human
be
includ
poultri
farmer
peopl
direct
contact
highli
contagi
ib
virus
chicken
c
studi
use
alpha
macaqu
amount
sar
coronaviru
viru
scv
use
challeng
median
tissu
cultur
infecti
dose
tcid
ml
pb
administ
intratrach
howev
mention
public
whether
prechalleng
titrat
viru
perform
import
establish
amount
challeng
viru
provok
diseas
eventu
death
therefor
start
experi
titrat
challeng
viru
monkey
perform
order
determin
amount
viru
produc
clinic
symptom
infect
anim
overdos
appli
real
effect
treatment
demonstr
insuffici
challeng
viru
use
result
becom
avail
extrem
import
vaccin
viru
free
microorgan
ib
live
vaccin
viru
therefor
product
passag
specif
pathogen
free
spf
embryon
egg
prerequisit
e
propos
challeng
vaccin
monkey
day
vaccin
challeng
scv
titrat
macaqu
see
point
c
propos
base
like
immedi
effect
vaccin
day
immunostimul
mechan
week
protect
observ
heterolog
crossprotect
activ
vaccin
viru
without
question
care
consider
relev
offici
health
author
must
given
anim
live
viru
vaccin
appli
human
be
applic
ib
vaccin
strain
h
human
restrict
hcw
person
risk
yet
show
sign
diseas
consid
candid
vaccin
clinic
symptom
observ
method
treatment
administr
alpha
recommend
